Nifty Pharma Stocks

The table below shows the Nifty Pharma Stocks List with Highest Market Cap.

Content:

• Nifty Pharma Stocks Weightage 
• Introduction to Nifty Pharma Stocks List 
• Nifty Pharma Stocks – FAQ

Nifty Pharma Stocks Weightage

The following table illustrates the Nifty Pharma Stocks arranged by weightage in descending order.

Introduction to Nifty Pharma Stocks List

Sun Pharmaceutical Industries Ltd

The market capitalization of Sun Pharmaceutical Industries Ltd is ₹374,596.17. Its one-month return percentage is 18.39%. The one-year return percentage is 60.54%. The deviation from its 52-week high is 0.46%. The stock holds a weightage of 25.47%.

Sun Pharmaceutical Industries Limited, headquartered in India, is a specialized generic pharmaceutical firm. The company’s core operations involve the manufacturing, development, and promotion of a broad spectrum of branded and generic formulations as well as active pharmaceutical ingredients (APIs). 

It maintains a comprehensive and diverse product lineup of generic and specialty medications, catering to various chronic and acute medical conditions. Leveraging its vertically integrated network, Sun Pharma can manufacture a wide array of pharmaceuticals, encompassing oncology, hormones, peptides, and steroidal drugs.

Dr Reddy’s Laboratories Ltd

The market capitalization of Dr. Reddy’s Laboratories Ltd is ₹107,270.41. Its one-month return percentage is 12.60%. The one-year return percentage is 44.78%. The deviation from its 52-week high is 0.81%. The stock holds a weightage of 12.39%.

Dr. Reddy’s Laboratories Limited, headquartered in India, is a renowned global pharmaceutical firm. Its offerings span a diverse range of products and services, encompassing active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars, and over-the-counter (OTC) medications. 

The company focuses on several key therapeutic areas, including gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy operates through distinct segments: Pharmaceutical Services and Active Ingredients, Global Generics, and Others. 

Cipla Ltd

The market capitalization of Cipla Ltd stands at ₹118,392.06. Its one-month return percentage is 4.93%. Over the past year, the return percentage is 52.70%. The deviation from its 52-week high is 1.09%. This stock holds a weightage of 11.79%.

Cipla Limited, headquartered in India, primarily focuses on pharmaceuticals. Its operations are divided into two main segments: Pharmaceuticals and New Ventures. Within the Pharmaceuticals segment, the company is involved in the development, manufacturing, sale, and distribution of generic or branded generic drugs, along with Active Pharmaceutical Ingredients (API). 

The New Ventures segment encompasses consumer healthcare, biosimilars, and specialty businesses. Cipla’s product range includes a variety of medications, such as complex generics, respiratory drugs, anti-retrovirals, urology medications, cardiology drugs, anti-infectives, and central nervous system (CNS) drugs. 

Divi’s Laboratories Ltd

The market capitalization of Divi’s Laboratories Ltd is ₹96,845.59. Its one-month return percentage is -0.54%. Over the past year, the return percentage is 26.97%. The deviation from its 52-week high is 11.69%. This stock holds a weightage of 7.78%.

Divi’s Laboratories Limited, an India-based company, specializes in producing and distributing active pharmaceutical ingredients (APIs), intermediates, and nutraceutical ingredients, primarily focusing on exports. 

Their diverse product portfolio encompasses Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, and numerous others. Apart from its generic operations, the company offers custom synthesis services, aiding pharmaceutical firms throughout various stages, from initial clinical trials to product launch and late-cycle management of patented drugs. 

Lupin Ltd

The market capitalization of Lupin Ltd amounts to ₹73,559.19. Its one-month return percentage stands at 11.92%. Over the past year, the return percentage has been notably high at 145.30%. The deviation from its 52-week high is 5.27%. This stock holds a weightage of 6.04%.

Lupin Limited, headquartered in India, specializes in producing, developing, and global marketing a diverse range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). 

Operating across various therapeutic segments such as Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives, and Nonsteroidal Anti-Inflammatory Drug therapy, as well as Anti-TB and Cephalosporins, the company and its subsidiaries maintain manufacturing facilities in India, the United States of America, Mexico, and Brazil.

Aurobindo Pharma Ltd

The market capitalization of Aurobindo Pharma Ltd stands at ₹61,160.27. Its one-month return percentage is -9.74, while its one-year return percentage is 123.22. The stock is currently 12.77% away from its 52-week high. Additionally, the weightage of the stock is 5.38%.

Aurobindo Pharma Limited, headquartered in India, primarily focuses on the manufacturing and marketing active pharmaceutical ingredients, branded and generic pharmaceuticals, and associated services. 

The company’s product range spans seven therapeutic/product categories, including Central Nervous System (CNS), Antiretrovirals (ARVs), Cardiovascular (CVS), SSP – Orals & Sterile, Anti-infectives, Anti-diabetics, and Cephalosporins – Orals. 

Alkem Laboratories Ltd

The market capitalization of Alkem Laboratories Ltd amounts to ₹64,817.98. Over the past month, the stock has shown a return percentage of 11.31, while its one-year return percentage stands at 65.51. Currently, the stock is 1.82% away from its 52-week high. Furthermore, the weightage of the stock is 4.17%.

Alkem Laboratories Limited, an India-based firm, is actively involved in the pharmaceutical sector with a global presence. Its core activities revolve around researching, producing, and distributing pharmaceutical and nutraceutical goods. 

Alkem offers a diverse range of products spanning various therapeutic categories, including Anti Infective, Dermatology, Diabetology, Cardiology, Gastroenterology, Osteoporosis, Rheumatology, Vitamins, Mineral, and Nutrition. 

Torrent Pharmaceuticals Ltd

The market capitalization of Torrent Pharmaceuticals Ltd is ₹88,907.92. Its one-month return percentage is 2.68%. Over the past year, the return percentage is 77.32%. The deviation from its 52-week high is 2.78%. This stock holds a weightage of 3.85%.

Torrent Pharmaceuticals Limited, an Indian pharmaceutical firm, specializes in a diverse range of therapeutic areas, including cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins, minerals, nutrients (VMN), anti-diabetes (AD), pain relief, gynecology, and dermatology. 

The company is extensively involved in the research, development, manufacturing, marketing, and global distribution of branded and generic pharmaceutical formulations. 

Zydus Lifesciences Ltd

The market capitalization of Zydus Lifesciences Ltd amounts to ₹93,451.75. Its one-month return percentage is 27.42%. Over the past year, the return percentage is 97.34%. The deviation from its 52-week high is 1.49%. This stock holds a weightage of 3.20%.

Zydus Lifesciences Ltd., an Indian-based life sciences company, is involved in various activities, including research and development, manufacturing, marketing, and sales of a range of pharmaceutical products. 

These products encompass finished dosage human formulations like generics and specialty formulations, including biosimilars and vaccines, active pharmaceutical ingredients (APIs), animal healthcare items, and consumer wellness products. 

IPCA Laboratories Ltd

The market capitalization of IPCA Laboratories Ltd is ₹30,893.56. Its one-month return percentage is 14.48%. Over the past year, the return percentage is 48.52%. The deviation from its 52-week high is 3.80%. This stock holds a weightage of 2.50%.

Ipca Laboratories Limited, headquartered in India, is a pharmaceutical firm producing and distributing more than 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) across diverse therapeutic categories. 

The company’s API portfolio includes compounds like Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol.

Nifty Pharma Stocks – FAQ

How many stocks are there in Nifty Pharma?

The Nifty Pharma Index reflects the performance of the pharmaceutical sector, consisting of 20 companies listed on the National Stock Exchange of India (NSE).

Which are the top 5 pharma stocks in India?

The top five companies in the pharma stocks based on market capitalization are Sun Pharmaceutical Industries Ltd, Cipla Ltd, Dr Reddy’s Laboratories Ltd, Divi’s Laboratories Ltd, and Zydus Lifesciences Ltd.

Can we buy Nifty pharma index?

Yes, investors can purchase the Nifty Pharma Index through various financial instruments such as exchange-traded funds (ETFs) and index funds offered by brokerage firms and financial institutions.

How to invest in pharma index?

Investing in the pharma index can be done through various means, such as index funds, exchange-traded funds (ETFs), or structured products designed to replicate the index’s performance.

What is the difference between Nifty pharma and Nifty Healthcare?

The difference between Nifty Pharma and Nifty Healthcare lies in their respective focuses. Nifty Pharma specifically tracks the performance of pharmaceutical companies, while Nifty Healthcare encompasses a broader spectrum, including pharmaceutical, healthcare services, and biotechnology firms.

When was Nifty Pharma launched?

Nifty Pharma was launched in July 2005.

We hope you’re clear on the topic, but there’s more to explore in stocks, commodities, mutual funds, and related areas. Here are important topics to learn about.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.